Phase 3Completed

Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)

A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia

Sponsor
Organon and Co (Industry)
Enrollment
2,815 enrolled
Conditions
Hypercholesterolemia
Interventions
MK0653A, ezetimibe (+) simvastatin; Comparator: Rosuvastatin
Ages
adults, older adults
Registry
NCT00090298

Full record on ClinicalTrials.gov

From the registry

A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.

Primary outcomes

  • LDL-C lowering efficacy after 6 weeks.

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started